Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations - Wikidata - thesis-toulmin - TriplyDB

Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations

Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations

http://www.wikidata.org/entity/Q28250725

about

Mitochondrial Stat3, the Need for Design Thinking Medical case reports in the age of genomic medicine Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Eosinophilia Associated with Disorders of Immune Deficiency or Immune Dysregulation Approaches to Managing Autoimmune Cytopenias in Novel Immunological Disorders with Genetic Underpinnings Like Autoimmune Lymphoproliferative Syndrome Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity Newly recognized Mendelian disorders with rheumatic manifestations Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies Flow Cytometry, a Versatile Tool for Diagnosis and Monitoring of Primary Immunodeficiencies Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis ERBIN deficiency links STAT3 and TGF-β pathway defects with atopy in humans.FOXP3+ Tregs require WASP to restrain Th2-mediated food allergy Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings.Editorial: Current Challenges in Immune and Other Acquired Cytopenias of Childhood Advances in the Care of Primary Immunodeficiencies (PIDs): from Birth to Adulthood.MRL Strains Have a BAFFR Mutation without Functional Consequence.Genetics of allergy and allergic sensitization: common variants, rare mutations IL-27 Induces Th17 Differentiation in the Absence of STAT1 Signaling The Ying and Yang of STAT3 in Human Disease A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation.Signal transducer and activator of transcription 3: a year in review.Copa Syndrome: a Novel Autosomal Dominant Immune Dysregulatory Disease.STAT5B deficiency: Impacts on human growth and immunity STAT3 in the systemic inflammation of cancer cachexia.Genetic Diagnosis Using Whole Exome Sequencing in Common Variable Immunodeficiency.The plethora, clinical manifestations and treatment options of autoimmunity in patients with primary immunodeficiency.Up, Down, and All Around: Diagnosis and Treatment of Novel STAT3 Variant.Studying human immunodeficiencies in humans: advances in fundamental concepts and therapeutic interventions.Genomics of Immune Diseases and New Therapies.Update on Diffuse Lung Disease in Children.From Genes to Mechanisms: The Expanding Spectrum of Monogenic Disorders Associated with Inflammatory Bowel Disease.Autoimmune and Lymphoproliferative Complications of Common Variable Immunodeficiency.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children.STAT3 signaling in immunity.Autoimmunity and Primary Immunodeficiency Disorders.STAT3 promotes CD1d-mediated lipid antigen presentation by regulating a critical gene in glycosphingolipid biosynthesis.Predispositions to Lymphoma: A Practical Review for Genetic Counselors.Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

P2860

Q26750616-D620372F-C284-44E5-9400-CDE6889F60FD Q26774876-40D9A002-2833-4A10-8A19-1E742E1211A0 Q26775111-6A6DF227-BBE2-477B-BB63-66899F61EDCD Q26799603-B88C09EF-81F1-452B-BE79-E129A6352A8F Q26799956-93AC3040-1D1C-4713-A1A1-509D6298EEC6 Q26863295-091B82BA-B108-420D-9BA2-29B17CABA759 Q26996730-A1E96536-3098-4DE0-8316-EA1090292930 Q28066193-A98476C3-F1EB-4AC4-8731-E39F1ED23355 Q28076919-A18237C9-A0FF-4A46-AD9A-C758422FFF20 Q28383324-B253B502-E685-409D-8741-42C83156ABE6 Q30274910-F105A85D-0C3F-49C7-926E-639D81AF964B Q30354566-E9676AF6-DC4F-4FFC-880E-1C0F0CF75F14 Q33425862-6EE62038-A61B-49A6-9577-A774C7DF1C69 Q33429970-DCCD2F0A-B13E-40C8-B32B-BA48A1FCAB6D Q33849434-C5A86D5A-608A-4C9B-BC2C-00D0ECE967D1 Q36009582-0CD9A5FA-5456-48F7-A6E0-858B89E20FC7 Q36176674-B90AB165-759E-4761-BDB4-0A6588EF7C83 Q36177032-DEA21490-2133-4894-B13D-B35E0F27F777 Q36236873-84FA270E-1355-4DD4-9610-1AC5F07D6656 Q36299574-F78F1D18-CE3A-45A1-AC84-6F7911BDB909 Q36684441-5B42866C-67DC-4D67-8200-319CCBBCE3FC Q36828440-ABA1E16B-589B-4C04-8C42-FB119CE24467 Q36840204-74E2AD80-E21D-40E8-8413-41F14923455B Q36901910-83B459F0-F349-4C4A-96D3-509D0259AA17 Q36995669-992E6CFC-0DA3-4D94-A90B-375503627082 Q37591931-CB0A82FE-45CC-4842-8D60-77ECAB7E26FB Q37695336-55731963-D5F0-4297-A987-85E222873C1B Q37730201-84F5F204-7CE1-42FD-8B0D-9B40AECD07AB Q38560780-3156CACF-D7D4-4603-A346-8F4F77A25D56 Q38616574-5D77E8D2-8D59-41E5-8424-1037107AE41B Q38619050-69F62ABF-B2FB-459B-B1D3-E4EDD454E34A Q38726509-D7AF575F-DD0E-4BF3-8A52-BFE64B5D8803 Q38751230-9AFD7B1A-15EC-4A0F-8B37-96AAAFAF5302 Q38823961-8B6FC146-756B-4D0E-BF58-8254480350DB Q38835846-3EB6C71B-0933-4099-A5B5-D83816E61CEA Q38841123-0830DE45-0FF6-49FC-8B31-E7D6939A5CEA Q38844774-7EBF968E-3AE7-48FD-9F56-C7597131C9CC Q38855962-723969A0-1C05-4FD5-89D7-4D29096780B2 Q38868306-E6E33F98-0BCE-4536-B8C7-03659C086291 Q38962315-E8DD0CC8-2FA6-4EA0-AAF4-BA87AF929040

P2860

Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations

http://www.wikidata.org/entity/Q28250725

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@ast

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@en

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@nl

type

label

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@ast

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@en

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@nl

prefLabel

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@ast

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@en

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@nl

P1433

Q28250725-E67793EF-5695-4E40-AE91-B7C337814724

P1476

Q28250725-50C8C04B-D7A4-49B4-AB6E-2BFF8D9966E1

P2093

Q28250725-05BFAFCC-FCE9-4F94-9E50-6812F5C7A6C1

Q28250725-084A6A51-B768-4767-B52E-3E8AB045DD33

Q28250725-118EAF86-2248-4A85-9176-6251ADB8279C

Q28250725-24E23184-6F28-4C35-B687-025E595D83BF

Q28250725-24EA1D43-504B-4E41-ABBF-7E389A4E8BD1

Q28250725-37B31FCD-432D-48CE-AAFA-2AE129129710

Q28250725-3874223F-01C3-4DE8-9002-8636763BD79D

Q28250725-3D7516E9-C825-40CE-9836-5E4FE74323DD

Q28250725-4B79A8C8-5C95-48CD-AC3B-CAC7739D6782

Q28250725-4CD6EFA5-B9B1-498E-99C0-006A01F32CA2

P2860

Q28250725-12493968-D100-4625-9D42-A2DFFB387BBA

Q28250725-2CC078C0-EC33-4EA1-AFE8-609CAE2993C2

Q28250725-2FBAE3C8-841B-4293-9125-E823A38D1526

Q28250725-30ED8B27-9247-45BA-BA7E-369EFA5CBF6A

Q28250725-32CBDE9B-EB4B-4C57-B367-D8A7FA051359

Q28250725-360C5731-E117-4AAC-B46F-7FCD8B5AF006

Q28250725-4077BA03-B254-4C8A-B4AC-B4AF908868FC

Q28250725-551673E3-22A7-418B-B3A5-6CA2589CF4CE

Q28250725-5C314539-DA54-4312-A215-8505398152FA

Q28250725-600F1E0D-CEA8-4287-AEA2-05137ABB745D

P304

Q28250725-35A35C9C-4530-4A59-AD04-869D5BF73D48

P31

Q28250725-4B517F65-349A-4720-AE70-7163FD028F60

P3181

Q28250725-8797AA43-DC10-4953-8710-48465FC4AE9F

P356

Q28250725-BB0184AA-D19B-4F73-A8AA-7003BB7DB1E3

P407

Q28250725-A9971903-847B-4CC0-9DB9-86372D120438

P433

Q28250725-DE0FD71F-E058-43B7-A323-F8351948BB22

P478

Q28250725-386B1452-68AF-4A53-8460-4BDD8AC5EDC5

P50

Q28250725-20189A61-626F-4615-A9F2-E5ED14996F8A

Q28250725-62509866-96AC-4439-A366-B6A982055BD3

Q28250725-6B59D255-70D4-411A-BCA8-2124A86EFD86

Q28250725-94674C66-5700-4626-BDA6-BD3130777AA7

Q28250725-B0D65777-B1A6-407C-AE5A-A71464C6EE2E

Q28250725-BA6EF700-E281-41E9-809A-8740DE1302B2

Q28250725-CE0924E4-D259-4027-9DF2-DA550D3F58CB

Q28250725-EFE2CF63-70EE-457F-9EF9-FC3E44DF3FC7

Q28250725-F3C09FAD-C4D6-4DF9-960C-7AD9E152CD58

P577

Q28250725-5D3BDED9-2F52-4EE7-A51F-E3C1893D79FD

P5875

Q28250725-171E3A23-3811-438E-913A-985D65690A46

P698

Q28250725-12A03213-60CF-499B-89EC-00A274F7B2E8

P921

Q28250725-CD0BD2C9-0583-43E7-91FC-25F0B4936CF1

P932

Q28250725-2E8F483F-9E6F-44B1-A3DA-63D7FD3D97AD

P3181

P356

BLOOD-2014-09-602763

P1433

P1476

Early-onset lymphoproliferatio ...... AT3 gain-of-function mutations

@en

P2093

Alexander Vargas-Hernandez

http://www.w3.org/2001/XMLSchema#string

Andrew J Cant

http://www.w3.org/2001/XMLSchema#string

Andrew J White

http://www.w3.org/2001/XMLSchema#string

Asbjørg Stray-Pedersen

http://www.w3.org/2001/XMLSchema#string

Carol J Saunders

http://www.w3.org/2001/XMLSchema#string

Chi A Ma

http://www.w3.org/2001/XMLSchema#string

Christina E Ciaccio

http://www.w3.org/2001/XMLSchema#string

Darrell L Dinwiddie

http://www.w3.org/2001/XMLSchema#string

George Makedonas

http://www.w3.org/2001/XMLSchema#string

Gøri Perminow

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic STAT3 mutations in large granular lymphocytic leukemia

STAT3 mutations in the hyper-IgE syndrome

Stats: transcriptional control and biological impact

Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.

Elevated double negative T cells in pediatric autoimmunity

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases.

A novel STAT1 mutation associated with disseminated mycobacterial disease.

JAKs and STATs in immunity, immunodeficiency, and cancer.

P304

591-599

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

846578

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2014-09-602763

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

Elisha Roberson

Stephen F Kingsmore

Julie E. Niemela

Jonathan J. Lyons

Kenneth L McClain

Michael P O'Connell

P577

2014-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268524484

http://www.w3.org/2001/XMLSchema#string

P698

25359994

http://www.w3.org/2001/XMLSchema#string

P921

P932

4304103

http://www.w3.org/2001/XMLSchema#string